# Europe PMC: a gold and green OA repository

**Promoting open access to research outputs** 

Making 100% of scientific publications available under open access: how can that objective be achieved?

5<sup>th</sup> Couperin's Open Access meeting – January 24/25, 2013

Robert Kiley, Wellcome Trust r.kiley@wellcome.ac.uk



# Agenda



- 1. Brief overview of Europe PMC
- 2. Discuss how content is added to the repository
- 3. Discuss Wellcome experience of working with publishers
- 4. Consider costs of "gold", OA publishing
- 5. Highlight some of the unique functionality Europe PMC offers
- 6. Invite other research funders to join Europe PMC

# **Europe PubMed Central (Europe PMC)**

- A service of the <u>Europe PMC Funders' Group</u> working in partnership with <u>European Bioinformatics</u> <u>Institute</u>, <u>University of Manchester</u> <u>British Library</u> in cooperation with the NCBI.
- It includes content provided to the <u>PubMed Central</u> <u>International archive</u> by *participating publishers*
- 19 funders mandate deposition of research outputs
   into Europe PMC
  - including ERC, MRC, Wellcome Trust, CR-UK, FWF
- Provides free access to over 2.6m full text, peerreviewed research papers, + 27m bibliographic records derived from PubMed, Agricola, Patents etc..

# How content is added to (Europe) PMC

- <u>Route A</u>: By <u>publishers</u> who make <u>all</u> their content available at the time of publication
  - (e.g. PLOS, BMC, eLife)
- <u>Route B</u>: By **publishers** who make *individual articles* available at the time of publication
  - (e.g. articles hybrid in hybrid journals)
- <u>Route C:</u> By **authors** who <u>self-archive</u> the author manuscripts in PMC/Europe PMC
  - (e.g. articles published in *Science*)
- <u>Route D:</u> By **publishers** who deposit the peer-reviewed manuscript (authors also have to "sign-off the deposit)
  - (e.g. Elsevier articles for NIH, NPG content for Wellcome [and others])

## How content is added to (Europe) PMC – by numbers



- Route A Publisher deposits (PMC Participants)
- Route B Publish deposits (Hybrid)
- Route C Author selfarchiving
- Route D Publisher deposition of author mss.

- 216,000 articles published in 2011, available in PMC
- 96% of this content deposited by publishers

# 2011 articles – how many articles have reuse licences?



• 48% of content added to PMC in 2011 was included in OA subset

# **Publishers: Wellcome experience**

- Wellcome has worked with publishers to specify services when OA fee is paid
  - Deposition of final version in PMC, in XML
  - Licence to facilitate re-use. From April 2013, must use CC-BY
- Also worked with publishers (e.g. NPG) when "green" version made available
  - Licence attached to each AAM deposited
  - Articles included in OA subset and available for download (in XML) via OAI and FTP
    - Link to <u>article</u> in Europe PMC or via <u>OAI</u> or via <u>FTP</u>
- But...also have to deal with publisher "take down" requests
- Set up "Publishers Panel" to discuss OA and scholarly publishing

# Wellcome Trust funded content in Europe PMC

- Compliance with OA mandate still disappointing (≈ 60%)
- 90% of this content is deposited by publishers
  - 10% of WT content is ingested via the self-archiving route



# **Strengthening Wellcome Trust policy (June 2012)**

- Specific sanctions for noncompliance:
  - withholding final payment on grants, pending assurance papers listed on final reports are compliant
  - requiring previous Trust-funded papers to be compliant before any funding renewals or new grants awards are activated
  - discounting non-compliant Trustfunded papers as part of a researcher's track record



# **Cost of OA publications (1)**

 Data published by University of Edinburgh<sup>1</sup> shows that over the last 4 years, average APC (for Wellcome Trust funded research papers) is £1741

Year	No.of articles	Total cost	Mean APC
2007/08	19	£32,712.85	£1,721.73
2008/09	38	£58,648.88	£1,543.39
2009/10	49	£90,304.78	£1,842.95
2010/11	67	£124,359.79	£1,856.11
2011/12	87	£146,687.10	£1,686.06
Total	260	£452,713.40	£1,741.21

Table 1: High-level details of the Wellcome Trust open access expenditure at UoE

1. Gold Open Access: Counting the Costs. Ariadne, 2012. http://www.ariadne.ac.uk/issue70/andrew

# **Cost of OA publications (2)**

- Analysis of OA spend (for Trust-funded research) from 30 UK universities shows that in 2011-12:
  - Some 1770 papers published under an author-pays model
  - Total cost to Trust of £3,181,278
  - Average APC =  $\pounds 1797$  (close to the Edinburgh data, of  $\pounds 1741$ ;  $\pounds 56$  difference)
- If 100% of Trust funded research incurred via an APC, total annual spend would be £8,985,000
  - i.e. £1797 x 5000 [number of papers attributed to Trust in an average year]
- Equates to **1.2%** of Trust's annual research spend
  - Annual research spend in 2011-12 was £746m
    - £9m / £746m = 1.2%
    - If our spend had been, say, £600m, then OA costs equal 1.5% of our research spend

# Benefits of a Europe-wide, subject-based repository

- Greater visibility of research findings
  - All articles in a single repository, fully accessible from PubMed and Google (as well as Europe PMC)
- Research process enhanced
  - Innovative features citation networks, articles integrated with underlying data-sets; text mining
- Greater compliance with funder mandate
  - Publishers can (and do) deposit in PMC
- Integration with Institutional Repositories (IR's)
  - Content can be shared with IR's
  - Integration with ORCID

# Visibility of research outputs

oogle	ap 1903 blood brain barrier	x.	Google			
	Web Images Maps Shopping More - Search tools About 2.230.000 results (0.46 seconds)	Google	p53 ~ Q			
	A general chemical method to regulate protein stability in the www.ncbi.nlm.nih.gov > NIHPA Author Manuscripts Share by M Iwamoto - 2010 - Cited by 24 - Related articles 24 Sep 2011 – The ability of TMP to cross the <b>blood-brain barrier</b> enables the tunable	Scholar	About 1,210,000 results (0.03 sec)			
	and pharmacokinetics of a novel dimerizer drug. AP1903, in healthy A general chemical method to regulate protein stability in the ukpmc. ac.uk/articles/PMC2943492/ 24 Sep 2010 – The ability of TMP to cross the <b>blood-brain barrier</b> enables the tunable and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy	Articles Legal documents Any time	WAF1, a potential mediator of <b>p53</b> tumor suppression. WS El-Deiry, T Tokino, VE Velculescu, DB Levy Cell, 1993, ukpmc.ac.uk The ability of <b>p53</b> to activate transcription from specific sequences suggests that genes induced by <b>p53</b> may mediate its biological role as a tumor suppressor. Using a subtractive hybridization approach, we identified a gene, named WAF1, whose induction was Cited by 6900 Related articles BL Direct All 9 versions Cite More ▼			
IPPF) ARGENT IN Regulated Homodimenzation Rit - ARIAD www.ariad.com/pdf/Reg_Homodimerization.pdf File Format: PDF/Adobe Acrobat The resulting third generation homodimerizers, AP1903 and the blood- in mice or whether it works in yeast or any other model organisms.	www.ariad.com/pdf/Reg_Homodimerization.pdf File Format: PDF/Adobe Acrobat The resulting third generation homodimerizers, <b>AP1903</b> and the <b>blood-brain barrier</b>	Since 2013 Since 2012 Since 2009 Custom range	p53 mutations in human cancers. M Hollstein, D Sidransky, B Vogelstein Science (New York,, 1991 ukpmc.ac.uk Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and			
	Intravenous safety and pharmacokinetics of a novel dimerizer drug lib.bioinfo.pl/paper:11504275 AP1903 is a novel gene-targeted drug that is being developed for use in The ability of TMP to cross the <b>blood-brain barrier</b> enables the tunable regulation of	Sort by relevance Sort by date	Cited by 6647 Related articles All 12 versions Cite More - <u>The mdm-2 oncogene product forms a complex with the <b>p53</b> protein and inhibits <b>p53</b>-mediated <u>transactivation</u>, J Momand, GP Zambetti, DC Olson, D George Cell, 1992 ukpmc.ac.uk</u>			
	Next 10 - Silicon Investor (SI) Invest This!           www.siliconinvestor.com/readmsgs.aspx?subjectid           29 Jun 2012 - CML is a cancer of the white blood cells which affects around 7,000           patients The company also has AP1903, which is being evaluated in patients brain           metastases, suggesting that LDK378 crosses the blood brain barrier.	<ul> <li>✓ include citations</li> <li>✓ Create alert</li> </ul>	A cellular phosphoprotein with an apparent molecular mass of 90 kg (p90) that forms a complex with both mutant and wild-type <b>p53</b> protein has been characterized, purified, and identified. The protein was identified as a product of the murine double minute 2 gene ( Cited by 2291 Related articles All 5 versions Cite More ▼ The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradati			
	Blood-brain barrier - Wikipedia, the free encyclopedia en.wikipedia.org/wiki/Blood-brain_barrier The blood-brain_brain_barrier extracellular f		p53. M Scheffner, BA Werness, JM Huibregtse, AJ Levine Cell, 1990 ukpmc.ac.uk The E6 protein encoded by the oncogenic human papillomavirus types 16 and 18 is one of two viral products expressed in HPV-associated cancers. E6 is an oncoprotein which cooperates with E7 to immortalize primary human keratinocytes. Insight into the Cited by 2836 Related articles All 6 versions Cite More ▼			
	Google		Germ line <b>p53</b> mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms D Malkin, FP Li, LC Strong, JF Fraumeni Jr Science (New York,, 1990 ukpmc.ac.uk Familial cancer syndromes have helped to define the role of tumor suppressor genes in the development of cancer. The dominantly inherited Li-Fraumeni syndrome (LFS) is of particular interest because of the diversity of childhood and adult tumors that occur in Cited by 2644. Related articles All 9 versions Cite More +			
			ратнону <u>Sofa</u> related anteres in a relation of the material pathogenesis <u>MS Greenblatt</u> , WP Bennett, M Hollstein, CC Harris - Cancer Research, 1994 - AACR The <b>p53</b> tumor suppressor gene has come to the forefront of cancer research because it is			

## **Research process enhanced – innovative services (1)**

About	Journal List	Grant Lookup	Resources	Help		E	
	Europe F Central	ubMed	gwa studies	5			V
Results	5				Ê <b>₪</b>		fc
Results: All	citations (12564)   Full	text articles (15766)	Sort by: Relevance   Da	ate Times Cited		Ê	Genome-wi
share (Pi Wa	ed controls.		cases of seven cor	nmon diseases	and 3,000		diseases ar (PMID:1755430) Abstract Cited By displa
(Pl Pu Da An	MID:17701901) Fre	I-Brown K, Thomas L, F		-			A second (PMID:1794 Internationa RA, Belmor Yang H, Zer Zhang B, Zh
<b>stud</b> (Pi Pri Na	<b>ies</b> . MID:16862161)	nalysis corrects for Plenge RM, Weinblatt I 104-909]	_		ociation		Defelice M, E, Winches Y, Sun W, V LM, Fan JB Leboeuf M, Koboldt DC
(Pl Ma Ca M, Mo Na	MID:19812666) Fre anolio TA, Collins FS, ardon LR, Chakravarti A		Hindorff LA, Hunter DJ, AE, Kong A, Kruglyak	L, Mardis E, Rotir	ni CN, Slatkin	2	Cites the followi Genome- (PMID:1571 Hirschhom Nat. Rev. G
	Sort rea	sults by	times c	ited			Evaluating (PMID:167* Barrett JC,

#### 'iew "Cited by" and "Cites the ollowing" data

ide association study of 14,000 cases of seven common nd 3.000 shared controls.

Citations 🕤 BioEntities Related Articles How does Europe PubMed Central derive its citations network? laying 25 of 2806 citations . Web of Science® times cited (2963)quired generation human haplotype map of over 3.1 million SNPs = 43122) al HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs nt JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, eng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, hang Q, Zhao H, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, , Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl ster E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Shen Wang H, Wang Y, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver , Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, , Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, , Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam Show all items

#### ring displaying 118 of 118 citations

wide association studies for common diseases and complex traits. 16906) JN, Daly MJ. Genet. [2005]

E

g coverage of genome-wide association studies (5099) Cardon LR. Nat. Genet. [2006]

## **Research process enhanced – innovative services (2)**



#### **Evidence Finder - text mining technologies**

#### **Acromine - disambiguation tool**

Refine your query (suggestions by Acromine) cardiopulmonary resuscitation cytochrome P450 reductase contraceptive prevalence rate cardio-pulmonary resuscitation computer-based patient record clinical prediction rule Central Population Register civil personal registration Continuous Plankton Recorder computerized patient record clinical pregnancy rate conjugate peak refinement calibrated population resistance clinical partial response complete pathological response after cardiorespiratory resuscitation Central Person Registry progesterone receptor Chasing, Preoccupation and Risked Relationships Cumulative percent revision critical perfusion rate Central Person Register Central Population Registry C-reactive protein

# **Integration with IR's**

- Already good working relationship between Europe PMC and initiatives such as Driver and OpenAire
  - Metadata from Europe PMC is harvested by <u>Driver</u>
  - OpenAire use the xml full text to mine content for FP7 funding information
- Content can be pulled from Europe PMC to an IR
  - OAI interface available (<u>http://europepmc.org/oai.cgi?</u>)
- Application under development that uses the Europe PMC web service to push metadata of full text articles (in OA subset) to Repository Junction (RJ)
  - RJ will then push articles to the relevant university IR
- Win-win situation
  - IR's can still showcase the outputs from their institution
  - Content becomes more easily discoverable through Europe PMC

# **Policy initiatives**

- UK Finch and RCUK
- Increasingly strong drive to support OA particularly the European Commission statement which set expectation for policies at national level
  - If Europe is to reap the benefits of wider access to scientific research results, clear policies are needed both national and European

 $http://ec.europa.eu/research/science-society/document\_library/pdf\_06/era-communication-towards-better-access-to-scientific-information\_en.pdf$ 

### But

 National initiatives and practices are still fragmented, thus preventing the European Union from realising its full research and innovation potential

http://ec.europa.eu/research/science-society/document\_library/pdf\_06/background-paper-open-access-october-2012\_en.pdf

• A Europe-wide repository will help realise these ambitions

# Invitation to join Europe PMC: rules of engagement

- Funder to develop/modify its OA mandate to specify that all funded, life sciences research, should be made available through the Europe PMC repository
- Funder policy is clarified such that if funds are used to cover OA publishing costs, then the *publisher* is required to deposit the paper in Europe PMC at the time of publication
  - This builds on the work already done by Trust and others
  - Ensures that articles published in hybrid journals, are made accessible and minable through Europe PMC
- Funder makes a contribution (based on its research spend) to contribute to the running costs of Europe PMC

# **Indicative costs (per annum)**

Funder	Annual Research Spent	Contribution to Europe PMC running costs (% of total costs)	Contribution to Europe PMC running costs (£/€) per annum
Small	£50m	2%	£14k/€17k
Medium	£175m	7%	£48k/€58k
Large	£650m	25%	£176k/€212k

Plus contribution to the R&D development budget

# Conclusion

- The Europe PMC Funders have developed a functionrich and well-used repository
- Europe PMC is:
  - cost effective
  - will help to increase visibility of research you fund
  - will provide you with the means of implementing your OA policies
- Funders invited to join Europe PMC and help shape the onward development of the service

